This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

CSCO - XIAMEN, CHINA, 19-23 September 2018

Oral Presentation: Sequencing of therapy following first-line afatinibin patients with EGFRmutation-positive (EGFRm+) non-small-cell lung cancer

Yi-Long Wu, Keunchil Park, Jaafar Bennouna, Michael Boyer, Toyoaki Hida, Vera Hirsh, Terufumi Kato, Shun Lu, Tony Mok, Kazuhiko Nakagawa, Kenneth O’Byrne, Martin Schuler, Denis Moro Sibilot, Eng-HuatTan, Hiroshi Tanaka, James C.-H. Yang, Li Zhang, Caicun Zhou, Angela Märten, Wenbo Tang, Nobuyuki Yamamoto
Presenter: JinjiYang

Wu_CSCO 2018_sequential therapies_Poster


Learn more about the science behind this poster in the videos, papers and other materials below.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu et al. Lancet Oncol. 2014 Feb;15(2):213-22

Afatinib versus gefitinib as fi rst-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park et al. Lancet Oncol. 2016 May;17(5):577-89

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Paz-Ares et al. Ann Oncol. 2017 Feb 1;28(2):270-277

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Hirsh et al. Ther Adv Med Oncol 2018, Vol. 10: 1–122018; 10:

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Girard et al. Future Oncol. 2018 May;14(11):1117-1132.


In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.